Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer
Our real-world experience with MIRV mirrors previously published data and suggests a benefit may also be seen in a more heavily pretreated population. Toxicities were similar to those previously reported, although our increased incidence of pneumonitis suggests care when treating patients with significant underlying cardiopulmonary comorbidities.
Authors
- Susan M. Lang (ORCID: https://orcid.org/0000-0003-0950-1138)
- Amer Karam (ORCID: https://orcid.org/0000-0003-1511-5583)
- Sahana Somasegar (ORCID: https://orcid.org/0000-0002-5111-7335)
- Prithvi Mruthyunjaya (ORCID: https://orcid.org/0000-0003-1087-9736)
- Isabel Beshar (ORCID: https://orcid.org/0000-0002-4367-836X)
- Babak Litkouhi (ORCID: https://orcid.org/0000-0003-3124-4350)
- Simone Sasse (ORCID: https://orcid.org/0000-0003-0168-2771)
- Talayeh Ghezelayagh (ORCID: https://orcid.org/0000-0001-6216-8501)
- EJ Adams (ORCID: https://orcid.org/0000-0001-5386-3182)
- Oliver Dorigo (ORCID: https://orcid.org/0000-0002-1976-5201)
- Filippos Vingopoulos (ORCID: https://orcid.org/0000-0003-3778-5473)
- C. McClung (ORCID: https://orcid.org/0000-0002-9194-0617)
Institutions
- Stony Brook Medicine (US)
- Smith-Kettlewell Eye Research Institute (US)
- Stanford University (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1016/j.gore.2025.101738
- Citations
- 2
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.40